Andrea Lobo,  —

The Aligning Science Across Parkinson’s (ASAP) initiative has launched a data-sharing platform that will make data on human brain samples available to researchers around the world, furthering research into Parkinson’s disease. The ASAP CRN Cloud includes several brain sequencing collections obtained from samples from four ASAP Collaborative…

The U.S. Food and Drug Administration (FDA) has given Iregene Therapeutics the green light to launch a clinical trial testing its cell therapy NouvNeu001, being developed for moderate to advanced Parkinson’s disease. According to the company, this marks a significant milestone, with NouvNeu001 becoming the world’s first…

NeuroOne Medical Technologies said the Centers for Medicare and Medicaid Services (CMS) granted a new ICD-10-PCS code to its OneRF Ablation procedure, a development the company said will lead to greater use of the technology. Effective Oct. 1, hospitals will be allowed to report inpatient procedures performed with…

A magnetic resonance imaging (MRI)-guided approach known as the ClearPoint Navigation System is being used in a Phase 1/2a clinical trial to enable the precise surgical delivery of ANPD001, an investigational stem cell therapy for Parkinson’s disease, its developer, Aspen Neuroscience, announced. The open-label ASPIRO trial…

Researchers at the University of Birmingham have shown that reducing dopamine signaling in the brain can impair people’s ability to recognize emotions or understand others’ mental states (mentalizing), symptoms that may be experienced by those with Parkinson’s disease. The study, “Disruption of dopamine D2/D3 system function impairs the…

Merck, in collaboration with the Michael J. Fox Foundation for Parkinson’s Research (MJFF), is providing a service to the scientific community to detect low levels of phospho-serine [pS65]-Ub, a biomarker associated with nerve cell dysfunction in people with Parkinson’s disease. The SMCxPRO platform is an ultrasensitive…

Patient enrollment is now complete in a Phase 2 trial that’s assessing the safety and efficacy of oral risvodetinib, being developed by Inhibikase Therapeutics to slow or stop the progression of Parkinson’s disease. The 201 trial (NCT05424276) has enrolled 120 participants across 32 sites in the U.S.,…

Scientists at the University of Dundee in Scotland said they have uncovered the mechanisms behind the activation of the PINK1 protein, an enzyme that protects the brain against nerve cell degeneration and the development of Parkinson’s disease. They discovered how PINK1, which detects damage in mitochondria — the cell’s…

A new ultra-high-performance brain imaging PET system called NeuroEXPLORER allows for the direct imaging of deep regions of the brain, that is, the brain nuclei, and may help diagnose and advance treatments for brain diseases, including Parkinson’s disease. The research was presented at the 2024 Society of Nuclear…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $595,000 grant to Alchemab Therapeutics to advance research on the therapeutic effects of an antibody targeting the prostaglandin pathway in people with Parkinson’s disease. The grant comes from the foundation’s Parkinson’s Disease Therapeutics Pipeline Program,…